Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities

Yongpeng Shi; Zeran Chen; Tingyu Fang; Xingyao Chen; Youpeng Deng; Hao Qin; Min Lian; Juntao Shen; Yuru Zong; Huikuan Chu; Constanze Hoebinger; Hao Guo; Zhongshang Yuan; Jie Zheng; Yongjian Zhou; Yue Pan; Beatriz G. Mendes; Sonja Lang; Tim Hendrikx; Suling Zeng; Hailong Cao; Ling Yang; Lianmin Chen; Peng Chen; Lei Dai; Hua Wang; Shi Yin; Shu Zhu; Xiong Ma; Bernd Schnabl; Hanqing Chen; Yi Duan

doi:10.1002/imt2.265

Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities

Yongpeng Shi, Zeran Chen, Tingyu Fang, Xingyao Chen, Youpeng Deng, Hao Qin, Min Lian, Juntao Shen, Yuru Zong, Huikuan Chu, Constanze Hoebinger, Hao Guo, Zhongshang Yuan, Jie Zheng, Yongjian Zhou, Yue Pan, Beatriz G. Mendes, Sonja Lang, Tim Hendrikx, Suling ZengHailong Cao, Ling Yang, Lianmin Chen, Peng Chen, Lei Dai, Hua Wang, Shi Yin, Shu Zhu, Xiong Ma, Bernd Schnabl, Hanqing Chen^*, Yi Duan^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter (Academic Journal) › peer-review

Abstract

Accumulating evidence indicates that the gut microbiota is intricately involved in the initiation and progression of human diseases, forming a multidirectional regulatory axis centered on intestinal microbiota. This article illustrates the challenges in exploring the role of the gut microbiota in inflammatory digestive diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and inflammatory bowel disease (IBD), and summarizes the existing microbiome-focused treatment strategies (probiotics, prebiotics, symbiotics, fecal microbiota transplantation, and bacteriophages therapy), emerging technologies (gut microbiome-on-a-chip and artificial intelligence), as well as possible future research directions. Taken together, these therapeutic strategies and technologies present both opportunities and challenges, which require researchers and clinicians to test the rationality and feasibility of various therapeutic modalities in continuous practice.

Original language	English
Article number	e265
Number of pages	8
Journal	iMeta
Early online date	31 Dec 2024
DOIs	https://doi.org/10.1002/imt2.265
Publication status	E-pub ahead of print - 31 Dec 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/imt2.265Licence: CC BY

Handle.net

Persistent link

Cite this

Shi, Y., Chen, Z., Fang, T., Chen, X., Deng, Y., Qin, H., Lian, M., Shen, J., Zong, Y., Chu, H., Hoebinger, C., Guo, H., Yuan, Z., Zheng, J., Zhou, Y., Pan, Y., Mendes, B. G., Lang, S., Hendrikx, T., ... Duan, Y. (2024). Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities. iMeta, Article e265. Advance online publication. https://doi.org/10.1002/imt2.265

@article{21d8f0be8e784b47a819eebd86e7acf3,

title = "Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities",

abstract = "Accumulating evidence indicates that the gut microbiota is intricately involved in the initiation and progression of human diseases, forming a multidirectional regulatory axis centered on intestinal microbiota. This article illustrates the challenges in exploring the role of the gut microbiota in inflammatory digestive diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and inflammatory bowel disease (IBD), and summarizes the existing microbiome-focused treatment strategies (probiotics, prebiotics, symbiotics, fecal microbiota transplantation, and bacteriophages therapy), emerging technologies (gut microbiome-on-a-chip and artificial intelligence), as well as possible future research directions. Taken together, these therapeutic strategies and technologies present both opportunities and challenges, which require researchers and clinicians to test the rationality and feasibility of various therapeutic modalities in continuous practice.",

author = "Yongpeng Shi and Zeran Chen and Tingyu Fang and Xingyao Chen and Youpeng Deng and Hao Qin and Min Lian and Juntao Shen and Yuru Zong and Huikuan Chu and Constanze Hoebinger and Hao Guo and Zhongshang Yuan and Jie Zheng and Yongjian Zhou and Yue Pan and Mendes, {Beatriz G.} and Sonja Lang and Tim Hendrikx and Suling Zeng and Hailong Cao and Ling Yang and Lianmin Chen and Peng Chen and Lei Dai and Hua Wang and Shi Yin and Shu Zhu and Xiong Ma and Bernd Schnabl and Hanqing Chen and Yi Duan",

year = "2024",

month = dec,

day = "31",

doi = "10.1002/imt2.265",

language = "English",

journal = "iMeta",

issn = "2770-596X",

publisher = "Wiley",

}

Shi, Y, Chen, Z, Fang, T, Chen, X, Deng, Y, Qin, H, Lian, M, Shen, J, Zong, Y, Chu, H, Hoebinger, C, Guo, H, Yuan, Z, Zheng, J, Zhou, Y, Pan, Y, Mendes, BG, Lang, S, Hendrikx, T, Zeng, S, Cao, H, Yang, L, Chen, L, Chen, P, Dai, L, Wang, H, Yin, S, Zhu, S, Ma, X, Schnabl, B, Chen, H & Duan, Y 2024, 'Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities', iMeta. https://doi.org/10.1002/imt2.265

TY - JOUR

T1 - Gut microbiota in treating inflammatory digestive diseases

T2 - Current challenges and therapeutic opportunities

AU - Shi, Yongpeng

AU - Chen, Zeran

AU - Fang, Tingyu

AU - Chen, Xingyao

AU - Deng, Youpeng

AU - Qin, Hao

AU - Lian, Min

AU - Shen, Juntao

AU - Zong, Yuru

AU - Chu, Huikuan

AU - Hoebinger, Constanze

AU - Guo, Hao

AU - Yuan, Zhongshang

AU - Zheng, Jie

AU - Zhou, Yongjian

AU - Pan, Yue

AU - Mendes, Beatriz G.

AU - Lang, Sonja

AU - Hendrikx, Tim

AU - Zeng, Suling

AU - Cao, Hailong

AU - Yang, Ling

AU - Chen, Lianmin

AU - Chen, Peng

AU - Dai, Lei

AU - Wang, Hua

AU - Yin, Shi

AU - Zhu, Shu

AU - Ma, Xiong

AU - Schnabl, Bernd

AU - Chen, Hanqing

AU - Duan, Yi

PY - 2024/12/31

Y1 - 2024/12/31

N2 - Accumulating evidence indicates that the gut microbiota is intricately involved in the initiation and progression of human diseases, forming a multidirectional regulatory axis centered on intestinal microbiota. This article illustrates the challenges in exploring the role of the gut microbiota in inflammatory digestive diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and inflammatory bowel disease (IBD), and summarizes the existing microbiome-focused treatment strategies (probiotics, prebiotics, symbiotics, fecal microbiota transplantation, and bacteriophages therapy), emerging technologies (gut microbiome-on-a-chip and artificial intelligence), as well as possible future research directions. Taken together, these therapeutic strategies and technologies present both opportunities and challenges, which require researchers and clinicians to test the rationality and feasibility of various therapeutic modalities in continuous practice.

AB - Accumulating evidence indicates that the gut microbiota is intricately involved in the initiation and progression of human diseases, forming a multidirectional regulatory axis centered on intestinal microbiota. This article illustrates the challenges in exploring the role of the gut microbiota in inflammatory digestive diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and inflammatory bowel disease (IBD), and summarizes the existing microbiome-focused treatment strategies (probiotics, prebiotics, symbiotics, fecal microbiota transplantation, and bacteriophages therapy), emerging technologies (gut microbiome-on-a-chip and artificial intelligence), as well as possible future research directions. Taken together, these therapeutic strategies and technologies present both opportunities and challenges, which require researchers and clinicians to test the rationality and feasibility of various therapeutic modalities in continuous practice.

U2 - 10.1002/imt2.265

DO - 10.1002/imt2.265

M3 - Letter (Academic Journal)

SN - 2770-596X

JO - iMeta

JF - iMeta

M1 - e265

ER -

Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities

Abstract

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this